Maxcyte (MXCT) Income from Continuing Operations (2020 - 2026)

Maxcyte (MXCT) has 7 years of Income from Continuing Operations data on file, last reported at 4750000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 53.71% year-over-year to 4750000.0 in Q1 2026; TTM through Mar 2026 was 39119000.0, a 6.39% increase from a year earlier, with the FY2025 full-year figure at 35258000.0, down 8.58% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 4750000.0, up from 9596000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for MXCT reached as high as 4750000.0 in Q1 2026 and fell as low as 30812400.0 in Q3 2022.
• Historically, Income from Continuing Operations has averaged 13373888.24 across 5 years, with a median of 10597000.0 in 2024.
• Across the five-year window, Income from Continuing Operations plunged 1139.94% in 2022 and jumped 81.56% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 28623600.0 in 2022, then soared by 81.56% to 5278000.0 in 2023, then slumped by 100.78% to 10597000.0 in 2024, then advanced by 9.45% to 9596000.0 in 2025, then soared by 50.5% to 4750000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 4750000.0 in Q1 2026, 9596000.0 in Q4 2025, and 12416000.0 in Q3 2025.